# MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

Clinical trial · Intellia Therapeutics

- Archive id: nct:NCT06128629
- Published: 2023-11-13
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT06128629
- Source URL: https://clinicaltrials.gov/study/NCT06128629
- Provenance: clinicaltrials

## Abstract

To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- status: RECRUITING
- phase: PHASE3
- study type: INTERVENTIONAL
- enrollment: 1200
- sponsor: Intellia Therapeutics
- conditions: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
- interventions: BIOLOGICAL: NTLA-2001; DRUG: Placebo
- start date: 2023-12-13
- start date type: ACTUAL
- primary completion date: 2027-12-01
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [CRISPR & Gene-Editing Therapies](https://space-kitty.com/topics/gene-editing-therapies)

Cited in dossiers:
- [CRISPR & Gene-Editing Therapies: State of the Field (October 2026)](https://space-kitty.com/dossiers/gene-editing-therapies)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.